Senators urge action on Beyfortus supply as RSV threat looms

Beyfortus (nirsevimab), along with vaccines, is one of the latest weapons against RSV.

Approved on July 17, 2023, AstraZeneca and Sanofi’s Beyfortus (nirsevimab-alip) occupies a unique niche as a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor for neonates and infants. With RSV rates surging, the drug quickly fell into a shortage. The CDC and FDA recently made available more than 77,000 additional doses of Beyfortus. Meanwhile, Senate Democrats Tammy Duckworth, Kirsten Gillibrand, Ron Wyden, Ed Markey, Richard Blumenthal, Jon Ossoff, and Elizabeth Warren pushed AstraZeneca and Sanofi for action regarding the supply shortage.

Unprecedented demand

Facing criticism for the supply shortfall, Sanofi noted it had encountered “higher than anticipated demand” and said it had an “aggressive supply plan” in place to exceed past performance of pediatric vaccine launches. AstraZeneca also noted…

Read more
  • 0